| 51 |
24772321 | Expression of ribonucleoside reductase subunit M1, but not excision repair cross-complementation group 1, is predictive in muscle-invasive bladder cancer treated with chemotherapy and radiation. | 2014 May |
2 |
| 52 |
25227833 | Expression of ERCC1, RRM1 and LRP in non-small cell lung cancers and their influence on chemotherapeutic efficacy of gemcitabine concomitant with nedaplatin. | 2014 |
1 |
| 53 |
25327655 | [Relationship between the efficacy of gemcitabine/cisplatin adjuvant chemotherapy and RRM1 protein expression in postoperative NSCLC patients]. | 2014 Jul |
4 |
| 54 |
25664003 | Gemcitabine sensitivity factors, hENT1 and RRM1 as potential prognostic biomarker for advanced biliary tract cancer. | 2014 |
3 |
| 55 |
22736490 | Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma. | 2013 Jan 1 |
2 |
| 56 |
23253379 | Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection. | 2013 Apr |
3 |
| 57 |
23261218 | The effect of the acid-sensitivity of 4-(N)-stearoyl gemcitabine-loaded micelles on drug resistance caused by RRM1 overexpression. | 2013 Mar |
2 |
| 58 |
23483975 | A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy. | 2013 |
8 |
| 59 |
23570983 | Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression. | 2013 Jul 10 |
2 |
| 60 |
23710668 | Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone. | 2013 May 27 |
3 |
| 61 |
23905902 | Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer? | 2013 Aug |
1 |
| 62 |
23982437 | Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients. | 2013 Nov |
2 |
| 63 |
23991987 | Predictive and prognostic roles of ribonucleotide reductase M1 in patients with pancreatic cancer treated with gemcitabine: a meta-analysis. | 2013 |
6 |
| 64 |
24045016 | Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer. | 2013 Nov |
2 |
| 65 |
24215511 | Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine. | 2013 Nov 12 |
3 |
| 66 |
24595080 | The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer. | 2013 Jan 1 |
2 |
| 67 |
25806229 | Predictive models for customizing chemotherapy in advanced non-small cell lung cancer (NSCLC). | 2013 Jun |
2 |
| 68 |
21889227 | RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis. | 2012 Mar |
6 |
| 69 |
22028294 | Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis. | 2012 May 1 |
2 |
| 70 |
22134350 | The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma. | 2012 Jan |
1 |
| 71 |
22173087 | Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer. | 2012 Feb |
1 |
| 72 |
22302408 | RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer. | 2012 May |
2 |
| 73 |
22330686 | The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. | 2012 Feb 14 |
1 |
| 74 |
22425885 | Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles. | 2012 Jun 15 |
2 |
| 75 |
22692073 | Expression of RRM1 and its association with resistancy to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma. | 2012 Oct |
5 |
| 76 |
22705007 | Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. | 2012 Sep |
1 |
| 77 |
23086647 | [Expression of RRM1 and ERCC1 genes in tumor tissues and peripheral blood lymphocytes of advanced non-small cell lung cancer]. | 2012 Sep |
1 |
| 78 |
23359225 | Individualized Chemotherapy in Advanced NSCLC Patients Based on mRNA Levels of BRCA1 and RRM1. | 2012 Sep |
2 |
| 79 |
28920258 | Response to gemcitabine-platinum chemotherapy by single nucleotide polymorphisms of RRM1 and ERCC1 genes in patients with non-small-cell lung cancer. | 2012 Feb |
2 |
| 80 |
20467918 | ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer. | 2011 Dec |
1 |
| 81 |
21163702 | The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. | 2011 Jul |
1 |
| 82 |
21220199 | Association of RRM1 -37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy. | 2011 Apr |
2 |
| 83 |
21264830 | DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma. | 2011 Jul 15 |
1 |
| 84 |
21264835 | Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer. | 2011 Jul 15 |
1 |
| 85 |
21370501 | RRM1 gene expression in peripheral blood is predictive of shorter survival in Chinese patients with advanced non-small-cell lung cancer treated by gemcitabine and platinum. | 2011 Mar |
4 |
| 86 |
21496433 | [Relations between RRM1 protein expression levels and effects of gemcitabine and cisplatin chemotherapy in advanced non-small cell lung cancer patients]. | 2011 Apr |
4 |
| 87 |
21529991 | Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines. | 2011 Nov |
1 |
| 88 |
21617862 | Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil. | 2011 Aug |
2 |
| 89 |
21642870 | Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum. | 2011 Aug |
3 |
| 90 |
21645463 | [Gemcitabine in RRM1-negative advanced refractory non-small cell lung cancer (NSCLC): a case report]. | 2011 Jun |
1 |
| 91 |
21893046 | Modulation of the ribonucleotide reductase M1-gemcitabine interaction in vivo by N-ethylmaleimide. | 2011 Sep 23 |
8 |
| 92 |
21940346 | Ribonucleotide reductase M1 expression in intrahepatic cholangiocarcinoma. | 2011 Sep-Oct |
4 |
| 93 |
19968494 | In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy. | 2010 Feb |
3 |
| 94 |
20211060 | [Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines]. | 2010 Jan |
2 |
| 95 |
20223551 | The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC). | 2010 Nov |
3 |
| 96 |
20226083 | RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy. | 2010 Mar 13 |
6 |
| 97 |
20438561 | Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients. | 2010 Dec |
1 |
| 98 |
20443070 | Impact of biomarkers on non-small cell lung cancer treatment. | 2010 Mar |
2 |
| 99 |
20811706 | Ribonucleotide reductase subunit M1 assessed by quantitative double-fluorescence immunohistochemistry predicts the efficacy of gemcitabine in biliary tract carcinoma. | 2010 Oct |
6 |
| 100 |
20868593 | [Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy]. | 2010 Aug |
1 |